Research and Development of
Therapeutic Apps in BrainTech/DTx

DTx by means of Open Innovation

MEDIASEEK has been working on BrainTech, which fuses neuroscience and IT, for a long time. We are developing our business in the DTx (digital therapeutics) field with the cooperation with our business partners, utilizing the neurofeedback technology that we have developed to regulate the brain's condition.
We develop apps for treatment with a focus on illnesses of the central nervous system such as dementia, depression, and chronic pain (back pain) that are deemed to be particularly difficult to treat with drugs.

Also, MEDIASEEK, which is registered as a "medical device manufacturer", makes use of its past experience in developing apps to provide design and development services for apps for treatments for medical institutions that are superior in terms of usability as well.

Medical device manufacturer and the development of apps for treatments

Apps for treatments are officially known as medical device programs. Like existing medical devices, medical device programs refer to programs that aim to diagnose and treat diseases and are under the regulation of the Pharmaceutical and Medical Devices Act.
Thus, unlike normal apps, they have to meet the standards of medical devices as stipulated by the Minister of Health, Labor, and Welfare in terms of quality, effectiveness, ensuring safety, and so on. To carry out the development, it must be registered as a medical device manufacturer in every prefecture, and also, with regards to app development, in line with a standard called JIS T 2304 (IEC62304), there must be a classification of the safety class and development must be carried out while documenting the app development process, including risk management

Our BrainTech/DTx Projects

At MEDIASEEK, we utilize BrainTech technology to research and develop therapeutic apps in the field of DTx.
As an open innovation-type joint business, for services' clinical trials, regulatory approvals, and sales, it partners with various research institutions, pharmaceutical companies, and so on.

Case Studies/Partners

With an estimated economic loss of up to three trillion yen, back pain is said to be a national disease in Japan, and according to an announcement by the Ministry of Health, Labor, and Welfare, almost all (about 85%) patients suffering from back pain who visit hospitals as outpatients have non-specific back pain for which the reason cannot be identified.
At Chiba University Hospital's pain center, to conduct research measuring the effectiveness of various treatments on non-specific chronic back pain sufferers, along with cognitive behavioral therapy and exercise therapy, a new type of treatment making use of neurofeedback was verified.
For this neurofeedback, "ALPHA SWITCH", a neurofeedback engine uniquely developed and provided by MEDIASEEK as well as a smartphone app equipped with that engine were adopted, and it turned out that neurofeedback plays the role of increasing the effectiveness of existing treatments such as cognitive behavioral therapy. The research paper has been made public in "Scientific Reports", an international journal.

Dementia is one of the biggest social issues in Japan. The number of patients with dementia is expected to increase, with the Cabinet Office estimating that by 2030 there will be more than 7 million dementia patients in the country.
Since no cure for the root cause of dementia has yet been established, it is important to detect mild dementia, with mild symptoms, at an early stage.
For this early detection, MEDIASEEK has partnered with a manufacturer developing devices to research and develop a service that screens for mild dementia based on brain responses using BrainTech technology.

IR and Public Relations

© 2018-2024MEDIASEEK,inc.